Innovating Works
SC1-PM-10-2017
SC1-PM-10-2017: Comparing the effectiveness of existing healthcare interventions in the adult population
Specific Challenge:Effective health care and prevention may be improved by additional evidence as to the most effective health interventions. Growing numbers of patients affected by chronic diseases also call for efficiently managing co-morbidities.
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 04-10-2016.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Número mínimo de participantes.
Esta ayuda financia Proyectos: Objetivo del proyecto:

Specific Challenge:Effective health care and prevention may be improved by additional evidence as to the most effective health interventions. Growing numbers of patients affected by chronic diseases also call for efficiently managing co-morbidities.


Scope:Proposals should compare the use of currently available preventative or therapeutic (pharmacological as well as non-pharmacological) healthcare interventions in adults[1]. While there is no restriction on the diseases or interventions to be the focus of proposals, preference will be given to proposals focusing on interventions with high public health relevance and socio-economic impact, i.e. interventions addressing conditions that are particularly frequent, may lead to co-morbidities, have a high negative impact on the quality of life of the individual and/or are associated with significant costs or where savings can be achieved. A cost effectiveness analysis must be included. Given the focus on existing interventions, proposals will aim to contribute to improve interventions, take decisions about the discontinuation of interventions that are less effective or less cost-effective than others, and make recommen... ver más

Specific Challenge:Effective health care and prevention may be improved by additional evidence as to the most effective health interventions. Growing numbers of patients affected by chronic diseases also call for efficiently managing co-morbidities.


Scope:Proposals should compare the use of currently available preventative or therapeutic (pharmacological as well as non-pharmacological) healthcare interventions in adults[1]. While there is no restriction on the diseases or interventions to be the focus of proposals, preference will be given to proposals focusing on interventions with high public health relevance and socio-economic impact, i.e. interventions addressing conditions that are particularly frequent, may lead to co-morbidities, have a high negative impact on the quality of life of the individual and/or are associated with significant costs or where savings can be achieved. A cost effectiveness analysis must be included. Given the focus on existing interventions, proposals will aim to contribute to improve interventions, take decisions about the discontinuation of interventions that are less effective or less cost-effective than others, and make recommendations on the most effective and cost-effective approaches. A comprehensive array of clinical and safety parameters, as well as health and socio-economic outcomes (e.g. quality of life, patient mortality, morbidity, costs, and performance of the health systems) for chosen populations should be assessed. Agreed core outcome sets (COS) should be used as endpoints in conditions where they already exist, in other cases efforts should be made to agree on such COS. Randomised controlled trials, pragmatic trials, observational studies, large scale databases and meta-analyses may be considered for this topic. Where relevant the study population should address gender as well as socio-economic differentials in health and/or any other factors that affect health equity.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.


Expected Impact:This topic is to provide the required evidence base for:

more effective and safer interventions at individual and population level; enhanced compliance with healthcare interventions in the adult population; the use of health technology assessment methodology in this target group. In particular:

Improvement of individual patient outcomes and health outcome predictability through tailoring of interventions. Improvement of guideline development for prevention or treatment of diseases and the management of comorbidities. Provision of more accurate information to patients, caregivers and prescribers.
Cross-cutting Priorities:Socio-economic science and humanitiesGender


[1]Screening and / or the involvement of elderly populations are not excluded.

ver menos

Temáticas Obligatorias del proyecto: Temática principal:

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: Specific Challenge:Effective health care and prevention may be improved by additional evidence as to the most effective health interventions. Growing numbers of patients affected by chronic diseases also call for efficiently managing co-morbidities. Specific Challenge:Effective health care and prevention may be improved by additional evidence as to the most effective health interventions. Growing numbers of patients affected by chronic diseases also call for efficiently managing co-morbidities.
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Purchase costs.
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
Subcontracting costs.
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Amortizaciones.
Activos.
Otros Gastos.
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 5:. Los elementos básicos de la innovación son integrados de manera que la configuración final es similar a su aplicación final, es decir que está listo para ser usado en la simulación de un entorno real. Se mejoran los modelos tanto técnicos como económicos del diseño inicial, se ha identificado adicionalmente aspectos de seguridad, limitaciones ambiéntales y/o regulatorios entre otros. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
Please read carefully all provisions below before the preparation of your application.
 
List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
Note also that a number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in some Horizon 2020 topics (to check funding conditions, follow the links to Australia, Brazil, Canada, China, Hong Kong & Macau, India, Japan, Republic of Korea, Mexico, Russia, Taiwan, USA*).
*Note that US participants in projects under the Horizon 2020 "Health, Demographic Change and Wellbeing" Societal Challenge are automatically eligible for EU-funding according to the provisions in the relevant work programme
 
Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme.
Proposal page limits and layout: Please refer to Part B of the standard proposal template.
 
Evaluation
3.1&nbsp; Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme,&nbsp;with the following exceptions: The thresholds for each criterion in the second stage of a two-stage call will be 4, 4 and 3. The cumulative threshold will be 12.<...
Please read carefully all provisions below before the preparation of your application.
&nbsp;
List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
Note also that a number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in some Horizon 2020 topics (to check funding conditions, follow the links to Australia, Brazil, Canada,&nbsp;China, Hong Kong &amp; Macau,&nbsp;India,&nbsp;Japan, Republic of Korea, Mexico, Russia, Taiwan, USA*).
*Note that US participants in projects under the Horizon 2020 &quot;Health, Demographic Change and Wellbeing&quot; Societal Challenge are automatically eligible for EU-funding according to the provisions in the relevant work programme
&nbsp;
Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme.
Proposal page limits and layout: Please refer to Part B of the standard proposal template.
&nbsp;
Evaluation
3.1&nbsp; Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme,&nbsp;with the following exceptions: The thresholds for each criterion in the second stage of a two-stage call will be 4, 4 and 3. The cumulative threshold will be 12.
3.2&nbsp;Submission and evaluation process: Guide to the submission and evaluation process
&nbsp; &nbsp; &nbsp;&nbsp;
Indicative timetable for evaluation and grant agreement:
Information on the outcome of two-stage evaluation:
&nbsp;&nbsp;&nbsp; For stage 1: maximum 3 months from the deadline for submission.
&nbsp;&nbsp;&nbsp; For stage 2: maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
&nbsp;
Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:
Research and Innovation Action:
Specific provisions and funding rates
Standard proposal template
Specific evaluation form
H2020 General MGA -Multi-Beneficiary
Annotated Grant Agreement
Essential information for clinical studies
&nbsp;
Additional provisions:
Horizon 2020 budget flexibility
Classified information
&nbsp;
Open access must be granted to all scientific publications resulting from Horizon 2020 actions.
Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
Open access to research data
The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in annex L of the Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.
Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.
Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.
- Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs.
- Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.
The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.
&nbsp;
Additional documents:
H2020 Work Programme 2016-17: Health, demographic change and wellbeing
H2020 Work Programme 2016-17: Dissemination, Exploitation and Evaluation
H2020 Work Programme 2016-17: General Annexes
Legal basis: Horizon 2020 - Regulation of Establishment
Legal basis: Horizon 2020 Rules for Participation
Legal basis: Horizon 2020 Specific Programme
&nbsp;
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda tiene efecto incentivador, por lo que el proyecto no puede haberse iniciado antes de la presentación de la solicitud de ayuda. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
H2020-SC1-2016-2017 Comparing the effectiveness of existing healthcare interventions in the adult population Specific Challenge:Effective health care and prevention may be improved by additional evidence as to the most effective health interventions...
Sin info.
SC1-PM-11-2016-2017 Clinical research on regenerative medicine
en consorcio:
Cerrada hace 8 años | Próxima convocatoria prevista para el mes de
SC1-PM-20-2017 Methods research for improved health economic evaluation
en consorcio: Specific Challenge:Health systems need to be resilient. They must be able to adapt effectively to changing environments, and tackle signific...
Cerrada hace 8 años | Próxima convocatoria prevista para el mes de
SC1-PM-03-2017 Diagnostic characterisation of rare diseases
en consorcio: Specific Challenge:Rare diseases are diseases which affect not more than 5 per 10 000 persons in the European Union. It is estimated that ra...
Cerrada hace 8 años | Próxima convocatoria prevista para el mes de
SC1-PM-16-2017 In-silico trials for developing and assessing biomedical products
en consorcio: Specific Challenge:In biomedical, pharmaceutical and toxicology research, the safety and efficacy of biomedical products is ultimately teste...
Cerrada hace 8 años | Próxima convocatoria prevista para el mes de
SC1-PM-19-2017 PPI for uptake of standards for the exchange of digitalised healthcare records
en consorcio: Specific Challenge:The use of interoperability standards is essential to the wider deployment of an EU eHealth single market. Despite previo...
Cerrada hace 8 años | Próxima convocatoria prevista para el mes de